Detailed financial statements for Bristol-Myers Squibb Company (BMY): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year: ten fiscal years free and up to 20 with Premium.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19.
Analysis Summary
Bristol-Myers Squibb Company reported revenue of $48.20B in the most recent fiscal year, growing at a 5-year CAGR of 2.5%.
Trailing-twelve-month margins: gross margin 70.2%, operating margin 28.3%, net margin 18.9%. Free cash flow grew at -0.7% CAGR over 5 years.
At the current price of $58.81, BMY trades at a P/E of 13.47 and an ROE of 46.75%. Market capitalisation stands at $120.1B, placing it among large-cap names.
Balance sheet quality for BMY: current ratio of 1.3, net debt of $36.47B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $12.85B represents 182% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.20B |
| Cost of Revenue | $4.93B | $5.82B | $6.49B | $8.89B | $20.82B | $19.62B | $19.67B | $19.65B | $20.87B | $13.94B |
| Gross Profit | $14.49B | $14.96B | $16.07B | $17.25B | $21.70B | $26.76B | $26.49B | $25.36B | $27.43B | $34.26B |
| Research & Development | $4.41B | $4.97B | $5.13B | $5.95B | $9.56B | $9.53B | $9.41B | $9.21B | $9.78B | $9.95B |
| Selling, General & Admin | $4.91B | $4.75B | $4.55B | $4.86B | $7.65B | $7.69B | $7.81B | $7.68B | $7.87B | $7.27B |
| Operating Expenses | $9.32B | $9.72B | $9.68B | $10.81B | $17.21B | $17.22B | $17.22B | $16.89B | $17.77B | $20.54B |
| Operating Income | $5.18B | $5.24B | $6.39B | $6.44B | $4.49B | $9.54B | $9.27B | $8.47B | $9.66B | $13.72B |
| EBITDA | $6.46B | $6.12B | $6.79B | $7.38B | $4.93B | $20.12B | $19.22B | $19.37B | $3.17B | $15.23B |
| Interest Expense | $167.0M | $196.0M | $183.0M | $656.0M | $1.42B | $1.33B | $1.23B | $1.17B | $1.95B | $1.89B |
| Pre-tax Income | $5.92B | $5.13B | $5.97B | $4.97B | -$6.87B | $8.10B | $7.71B | $8.44B | -$8.38B | $9.33B |
| Income Tax | $1.41B | $4.16B | $1.02B | $1.51B | $2.12B | $1.08B | $1.37B | $400.0M | $554.0M | $2.27B |
| Net Income | $4.46B | $1.01B | $4.92B | $3.44B | -$8.99B | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B |
| EPS | $2.67 | $0.61 | $3.03 | $2.02 | $-3.98 | $3.15 | $2.97 | $3.88 | $-4.41 | $3.46 |
| EPS (Diluted) | $2.65 | $0.61 | $3.03 | $2.01 | $-3.98 | $3.12 | $2.95 | $3.86 | $-4.41 | $3.45 |
| Shares Outstanding (Diluted) | $1.68B | $1.65B | $1.64B | $1.71B | $2.26B | $2.25B | $2.15B | $2.08B | $2.03B | $2.04B |
Income Statement (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Gross Profit | $8.79B | $8.41B | $8.07B | $9.25B |
| Operating Income | $3.64B | $2.81B | $3.37B | $4.09B |
| EBITDA | $4.61B | $2.88B | $4.25B | $4.94B |
| Net Income | $2.20B | $1.09B | $2.68B | $3.32B |
| EPS | $1.08 | $0.53 | $1.31 | $1.62 |
| EPS (Diluted) | $1.08 | $0.53 | $1.31 | $1.62 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Short-term Investments | $2.11B | $1.39B | $1.85B | $3.05B | $1.90B | $3.24B | $130.0M | $816.0M | $513.0M | $464.0M |
| Receivables | $5.54B | $6.30B | $5.75B | $7.68B | $10.55B | $12.52B | $13.94B | $15.26B | $14.42B | $14.53B |
| Inventory | $1.24B | $1.17B | $1.20B | $4.29B | $2.07B | $2.10B | $2.34B | $2.66B | $2.56B | $2.69B |
| Total Current Assets | $13.70B | $14.85B | $17.72B | $29.35B | $30.19B | $33.26B | $27.27B | $31.77B | $29.78B | $29.39B |
| Property, Plant & Equipment | $4.98B | $5.00B | $5.03B | $6.96B | $6.75B | $6.97B | $7.47B | $8.04B | $8.36B | $9.12B |
| Goodwill | $6.88B | $6.86B | $6.54B | $22.49B | $20.55B | $20.50B | $21.15B | $21.17B | $21.72B | $21.75B |
| Intangible Assets | $1.39B | $1.21B | $1.09B | $63.97B | $53.45B | $42.77B | $36.35B | $27.48B | $23.64B | $19.10B |
| Total Assets | $33.71B | $33.55B | $34.99B | $129.94B | $118.48B | $109.31B | $96.82B | $95.16B | $92.60B | $90.04B |
| Accounts Payable | $1.66B | $2.25B | $1.89B | $2.44B | $2.71B | $2.95B | $3.04B | $3.26B | $3.60B | $3.58B |
| Short-term Debt | $992.0M | $987.0M | $1.70B | $3.35B | $2.34B | $4.95B | $4.26B | $3.12B | $2.05B | $2.26B |
| Total Current Liabilities | $8.84B | $9.56B | $10.65B | $18.30B | $19.08B | $21.87B | $21.89B | $22.26B | $23.77B | $23.42B |
| Long-term Debt | $5.72B | $6.97B | $5.65B | $43.39B | $48.34B | $39.60B | $35.06B | $36.65B | $47.60B | $42.85B |
| Total Liabilities | $17.36B | $21.70B | $20.86B | $78.25B | $80.60B | $73.31B | $65.70B | $65.67B | $76.22B | $71.53B |
| Retained Earnings | $33.51B | $31.16B | $34.06B | $34.47B | $21.28B | $23.82B | $25.50B | $28.77B | $14.91B | $16.90B |
| Total Equity | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
| Total Debt | $6.71B | $7.96B | $7.35B | $47.54B | $51.67B | $45.60B | $40.72B | $41.46B | $51.20B | $47.14B |
| Net Debt | $358.0M | $1.15B | -$1.41B | $32.15B | $35.22B | $28.38B | $31.46B | $29.18B | $40.34B | $36.47B |
| Working Capital | $4.86B | $5.29B | $7.06B | $11.05B | $11.11B | $11.39B | $5.38B | $9.51B | $6.01B | $5.97B |
Balance Sheet (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Cash & Equivalents | $15.73B | $10.21B | $9.57B | $8.72B |
| Total Assets | $96.89B | $90.04B | $86.48B | $87.63B |
| Total Liabilities | $78.29B | $71.53B | $66.37B | $65.31B |
| Total Equity | $18.55B | $18.47B | $20.07B | $22.32B |
| Total Debt | $51.04B | $47.14B | $46.43B | $43.12B |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.51B | $975.0M | $4.95B | $3.46B | -$8.99B | $7.01B | $6.34B | $8.04B | -$8.93B | $7.05B |
| Depreciation & Amortization | $382.0M | $789.0M | $637.0M | $1.75B | $10.38B | $10.69B | $10.28B | $9.76B | $9.60B | $4.01B |
| Stock-based Compensation | $205.0M | $199.0M | $221.0M | $441.0M | $779.0M | $583.0M | $457.0M | $518.0M | $507.0M | $553.0M |
| Change in Working Capital | -$1.15B | $2.15B | $217.0M | $3.17B | $983.0M | -$1.26B | -$2.23B | -$1.91B | $810.0M | -$455.0M |
| Operating Cash Flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B |
| Capital Expenditure | -$1.22B | -$1.05B | -$951.0M | -$836.0M | -$753.0M | -$973.0M | -$1.12B | -$1.21B | -$1.25B | -$1.31B |
| Acquisitions | $975.0M | $10.0M | -$1.12B | -$9.09B | -$12.34B | -$862.0M | -$2.98B | -$260.0M | -$20.72B | -$2.87B |
| Stock Repurchased | -$231.0M | -$2.47B | -$320.0M | -$7.30B | -$1.55B | -$6.29B | -$8.00B | -$5.16B | 0 | 0 |
| Dividends Paid | -$2.55B | -$2.58B | -$2.61B | -$2.68B | -$4.08B | -$4.40B | -$4.63B | -$4.74B | -$4.86B | -$5.04B |
| Free Cash Flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B |
Cash Flow (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Operating Cash Flow | $6.31B | $1.97B | $1.10B | $3.39B |
| Capital Expenditure | -$320.0M | -$370.0M | -$347.0M | -$305.0M |
| Free Cash Flow | $5.99B | $1.60B | $757.0M | $3.09B |
| Dividends Paid | -$1.26B | -$1.26B | -$1.28B | -$1.29B |
| Stock-based Compensation | $139.0M | $133.0M | $146.0M | $135.0M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +6.9% | +8.6% | +15.9% | +62.6% | +9.1% | -0.5% | -2.5% | +7.3% | -0.2% | |
| Net Income Growth (YoY) | -77.4% | +388.6% | -30.1% | -361.6% | +177.8% | -9.5% | +26.8% | -211.5% | +178.8% | |
| EPS Growth (YoY) | -77.2% | +396.7% | -33.3% | -297.0% | +179.1% | -5.7% | +30.6% | -213.7% | +178.5% | |
| Shares Change (YoY) | -1.7% | -0.9% | +4.6% | +31.9% | -0.6% | -4.4% | -3.2% | -2.5% | +0.7% | |
| FCF Growth (YoY) | +129.0% | +44.9% | +20.6% | +80.3% | +14.5% | -21.6% | +5.9% | +10.2% | -7.9% | |
| Gross Margin | 74.6% | 72.0% | 71.3% | 66.0% | 51.0% | 57.7% | 57.4% | 56.3% | 56.8% | 71.1% |
| Operating Margin | 26.7% | 25.2% | 28.3% | 24.6% | 10.6% | 20.6% | 20.1% | 18.8% | 20.0% | 28.5% |
| EBITDA Margin | 33.3% | 29.4% | 30.1% | 28.2% | 11.6% | 43.4% | 41.6% | 43.0% | 6.6% | 31.6% |
| Net Margin | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| FCF Margin | 9.5% | 20.3% | 27.1% | 28.2% | 31.3% | 32.8% | 25.9% | 28.1% | 28.9% | 26.7% |
| Effective Tax Rate | 23.8% | 81.0% | 17.1% | 30.5% | -30.9% | 13.4% | 17.7% | 4.7% | -6.6% | 24.4% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $1.10 | $2.55 | $3.74 | $4.31 | $5.89 | $6.79 | $5.57 | $6.09 | $6.88 | $6.29 |
| Dividends Per Share | $1.52 | $1.56 | $1.60 | $1.56 | $1.80 | $1.96 | $2.16 | $2.28 | $2.40 | $2.47 |
| Shares Outstanding (Basic) | $1.67B | $1.65B | $1.63B | $1.71B | $2.26B | $2.22B | $2.13B | $2.07B | $2.03B | $2.04B |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | 46.75% |
| Return on Invested Capital | 15.47% |
| Return on Assets | 10.59% |
| Gross Margin | 70.16% |
| Operating Margin | 28.27% |
| Net Margin | 18.87% |
Financial Health
| Debt / Equity | 1.93 |
| Current Ratio | 1.53 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 2.30 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | 21.89 | 100.46 | 17.16 | 31.78 | -15.59 | 19.79 | 24.23 | 13.22 | -12.83 | 15.59 |
| P/B | 6.04 | 8.59 | 6.05 | 2.12 | 3.70 | 3.85 | 4.93 | 3.61 | 7.02 | 5.96 |
| P/S | 5.03 | 4.85 | 3.76 | 4.19 | 3.29 | 2.99 | 3.32 | 2.36 | 2.37 | 2.28 |
| Gross Margin | 74.6% | 72.0% | 71.3% | 66.0% | 51.0% | 57.7% | 57.4% | 56.3% | 56.8% | 71.1% |
| Operating Margin | 26.7% | 25.2% | 28.3% | 24.6% | 10.6% | 20.6% | 20.1% | 18.8% | 20.0% | 28.5% |
| Net Margin | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
Related companies: CI · CVS · ELV · GSK · HCA · MCK · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of BMY: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks